Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.
Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Mizuta S, Hashino S, Nomura T, Shikami M, Fukutani H, Ohe Y, Kosugi H, Shibayama H, Maeda Y, Fukushima T, Yamazaki H, Tsubaki K, Kukita T, Adachi Y, Nataduka T, Sakoda H, Yokoyama H, Okamoto T, Shirasugi Y, Onishi Y, Nohgawa M, Yoshihara S, Morita S, Sakamoto J, Kimura S; DADI Trial Group, Japan. Okada M, et al. Among authors: tsubaki k. Clin Lymphoma Myeloma Leuk. 2018 May;18(5):353-360.e1. doi: 10.1016/j.clml.2018.03.004. Epub 2018 Mar 15. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29610029 Free article. Clinical Trial.
Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.
Morita Y, Maeda Y, Yamaguchi T, Urase F, Kawata S, Hanamoto H, Tsubaki K, Ishikawa J, Shibayama H, Matsumura I, Matsuda M. Morita Y, et al. Among authors: tsubaki k. Cancer Sci. 2018 Oct;109(10):3209-3215. doi: 10.1111/cas.13739. Epub 2018 Aug 26. Cancer Sci. 2018. PMID: 30007103 Free PMC article. Clinical Trial.
Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation.
Seike K, Fujii N, Asano N, Ohkuma S, Hirata Y, Fujii K, Sando Y, Nakamura M, Naito K, Saeki K, Meguri Y, Asada N, Ennishi D, Nishimori H, Matsuoka KI, Tsubaki K, Otsuka F, Maeda Y. Seike K, et al. Among authors: tsubaki k. Transfusion. 2020 Mar;60(3):473-478. doi: 10.1111/trf.15664. Epub 2020 Jan 22. Transfusion. 2020. PMID: 31970799
Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.
Taniguchi Y, Tanaka H, Luis EJ, Sakai K, Kumode T, Sano K, Serizawa K, Rai S, Morita Y, Hanamoto H, Tsubaki K, Nishio K, Matsumura I. Taniguchi Y, et al. Among authors: tsubaki k. Int J Hematol. 2017 Nov;106(5):691-703. doi: 10.1007/s12185-017-2302-5. Epub 2017 Aug 5. Int J Hematol. 2017. PMID: 28780601 Clinical Trial.
241 results